These findings suggest that TIMELESS's tumor-promoting role is mediated through SIRT1 activation and glycolysis regulation, positioning TIMELESS as a potential therapeutic target for addressing metabolic anomalies in OSCC. This evidence concerns the gene SIRT1 and neoplasm.